Loyal Valley Capital

Core Medical Technology is a technology enterprise mainly engaged in the research, production, development, and sales of implantable left ventricular assist devices, extracorporeal ventricular assist devices, percutaneous interventional ventricular assist devices, and equipment. The company was founded in 2016 and is based in Shenzhen, China.

Sinovent, established in 2016, is a global biopharmaceutical company with headquarters in Suzhou, China, and offices in Beijing, China, and Boston, U.S.A. It specializes in developing advanced treatments for global healthcare challenges, with a focus on oncology, autoimmune diseases, and infectious diseases. Sinovent's portfolio comprises 12 products in various stages of development, leveraging its expertise in science, management, and finance to deliver innovative solutions to patients worldwide.

DPTechnology, founded in 2018 and based in Beijing, China, specializes in micro-scale industrial design through advanced molecular simulation technology. The company has developed a platform that integrates artificial intelligence with molecular simulation algorithms, aiming to enhance industrial and medical research. By providing users with innovative scientific tools, DPTechnology promotes efficiency and creativity in exploring complex research challenges, thereby establishing a new paradigm in both industrial research and clinical applications.

Chabaidao is a tea drink brand that aims to create surprises through product development and trendy gameplay.

Core Medical Technology is a technology enterprise mainly engaged in the research, production, development, and sales of implantable left ventricular assist devices, extracorporeal ventricular assist devices, percutaneous interventional ventricular assist devices, and equipment. The company was founded in 2016 and is based in Shenzhen, China.

Beijing Surgerii Technology Co., Ltd. specializes in the research, development, production, and sale of minimally invasive surgical robot systems in China. Founded in 2014 and based in Beijing, the company focuses on innovative technologies, particularly the next generation of flexible continuum robotic arms. Surgerii Technology aims to transform clinical practices through its single-hole and porous laparoscopic robot systems, enhancing the standard of care in minimally invasive surgeries. With a commitment to independent research and development, the company leverages its expertise in system design and integration to advance the medical equipment industry in China.

Bowang Pharmaceutical is an RNAi drug research and development platform focused on siRNA drug development.

Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the research and development and subversive production of rAAV gene drugs. Zhishan Weixin's therapeutic areas cover blood diseases, rare diseases, and other disease areas.

O-Net Technologies (Group) Limited is an investment holding company based in Shenzhen, China, specializing in the design, manufacture, and sale of optical networking components, modules, and subsystems for high-speed telecommunications and data communications systems. Founded in 2000, O-Net provides a diverse range of optical communication products, including amplifiers, couplers, connectors, and tunable filters, as well as data center solutions. Additionally, the company manufactures industrial application products such as fiber lasers, electronic cigarette accessories, and mobile phone parts. O-Net also engages in the production of automation equipment and offers coating solutions for consumer electronics. The company operates a research and development center in the United States and has a presence in China, Europe, North America, and other Asian countries. Since its listing on the Hong Kong Stock Exchange in 2010, O-Net has established itself as a key player in the high technology sector, particularly in optical networking and automation.

Jinyuansheng is a company that focuses on the development, smelting, and deep processing of energy metal mineral resources. Its core business includes the production of lithium-ion battery cathode precursor materials and the recycling of power batteries and materials. By leveraging scientific and technological advancements, Jinyuansheng aims to create innovative materials that support energy efficiency and contribute to a more sustainable environment. The company's activities are centered on the comprehensive utilization of metal resources and the development of environmentally friendly materials, positioning it as a key player in the lithium battery industry and in promoting greener practices.

Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of therapeutics aimed at addressing unmet medical needs, particularly in the areas of respiratory viral infections and viral hepatitis. Founded in 2013, the company focuses on developing innovative treatments, including AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences is committed to advancing antiviral drug research and development to serve both global and Chinese markets.

Frontera Therapeutics is a company specializing in adeno-associated virus (AAV) gene therapy, dedicated to creating a low-cost and scalable platform for the development and production of high-quality recombinant AAV therapies. The company focuses on commercializing cost-effective gene therapies aimed at treating a range of genetic disorders, including those affecting ophthalmology, liver, metabolic, and neuromuscular diseases. Frontera Therapeutics has established a robust product pipeline that encompasses multiple therapeutic areas, with various candidates at different stages of development. Through its innovative approach, the company aims to improve patient outcomes by making genetic therapies more accessible and affordable in the global market.

Alit Life Sciences is a supplier of advanced instruments, equipment, and technical services for the life sciences and biotechnology sectors. Established with a focus on delivering comprehensive solutions, the company has developed a range of products, including the Countstar IC1000 cell analyzer launched in 2011, along with various series such as Biotech, Altair, Rigel, and Mira. Alit provides an extensive array of laboratory instruments, testing reagents, and production equipment, supporting clients from research and development through to production. Additionally, the company acts as a supplier of overseas biological equipment, ensuring that customers have access to a complete set of supplies necessary for their operations in the biotech and life sciences industries.

MediLink Therapeutics is a China-based developer of antibody-drug conjugates (ADC) focused on cancer therapy. The company advances next-generation ADCs and aims to address unmet medical needs in China, while pursuing global value through multicenter clinical trials and cross-border collaborations. Its R&D center is in Suzhou.

Chen Xianggui is a catering brand and servicer that makes Lanzhou ramen and snacks, braised beef skewers, mutton, and other products.

Peijie Hotpot operates a chain of authentic Chongqing spicy hotpot restaurants, focusing on delivering genuine culinary experiences to its customers. The company specializes in catering management services and offers a variety of food-related services, including fast-moving food and cultural management. In addition to its restaurant operations, Peijie Hotpot is involved in entertainment supervision and hotel management, aiming to create a comprehensive dining and cultural experience. Through its commitment to authenticity and quality, Peijie Hotpot seeks to provide a distinctive taste of Chongqing cuisine to a diverse clientele.

ABclonal Inc. is a life science research and diagnostic reagents provider based in Woburn, Massachusetts, founded in 2016. The company specializes in offering a variety of biological research agents and services, including next generation sequencing library preparation kits, molecular biology products, catalog antibodies, catalog proteins, ELISA kits, and western blot tools and reagents. In addition to its extensive product range, ABclonal provides customized services related to peptides, antibodies, and proteins. The company distributes its products through a network of distributors across Europe, Asia, North America, and Oceania, aiming to enhance the quality of life science research with its high-quality offerings.

Tripod Preclinical Research is a Contract Research Organization that specializes in preclinical research services tailored for the biopharmaceutical industry. The company offers a comprehensive range of services, including nonhuman primate disease models, pharmacological efficacy assessments, early drug evaluations, and GLP toxicology. Tripod is committed to supporting global pharmaceutical companies, research and development enterprises, and medical device manufacturers in the evaluation of new chemical entities, food additives, biologics, pesticides, veterinary drugs, and cosmetics. Additionally, the organization provides technology support in areas such as translational medicine, clinical trials, biological analysis, and the management of biological sample banks, ensuring that its clients have the necessary resources to advance their research and development efforts effectively.

Hangzhou Sciwind Biosciences Co., Ltd. is a biotechnology company that focuses on the development and commercialization of protein and peptide-based drugs aimed at treating various diseases. Founded in 2017 and located in Hangzhou, China, the company targets multiple therapeutic areas, including diabetes, obesity, metabolic liver diseases, diabetic retinopathy, and neurodegenerative disorders. Sciwind's innovative drug candidates are particularly designed to address metabolic disorders, including non-alcoholic steatohepatitis, providing enhanced treatment options for physicians and their patients.

Leads Biolabs is a biotechnology company based in China that focuses on developing innovative antibody-based therapeutics for oncology and immunological diseases. Founded in 2014, the company is dedicated to addressing global unmet medical needs by creating biopharmaceutical products that enhance treatment outcomes for patients. Leads Biolabs has established a strong research and development pipeline, featuring over ten projects centered on monoclonal and bispecific antibodies aimed at cancer immunotherapy. Through its commitment to advancing tumor immunotherapy, the company strives to improve the medical treatment and overall conditions of patients facing cancer.

Alebund Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies for renal diseases and associated chronic conditions. The company focuses on researching and commercializing treatments for a variety of kidney-related ailments, including chronic kidney disease, dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified pipeline of drug candidates, Alebund Pharmaceuticals aims to deliver comprehensive, high-quality solutions to patients suffering from renal diseases, addressing both immediate and long-term healthcare needs in this critical area.

Abogen Biosciences, established in 2019 and headquartered in Jiangsu, China, specializes in the development of nucleic acid-based therapeutics, including RNA and DNA treatments, for combating cancer and infectious diseases.

JCET Group manufactures semiconductor products.

Hepagene Therapeutics is a biopharmaceutical company focused on developing innovative treatments for liver diseases. The company is dedicated to researching and creating therapies for conditions such as non-alcoholic steatohepatitis (NASH), chronic Hepatitis B infection, and liver cancer. Hepagene Therapeutics aims to address the significant unmet medical needs in the field of hepatology, striving to improve patient outcomes through its targeted drug development efforts.

EdiGene Inc. is a biotechnology company specializing in the development of genome editing technologies for therapeutic applications in cancer and various genetic diseases. Founded in 2015 and headquartered in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts, EdiGene focuses on both ex vivo and in vivo gene-editing therapies. The company has established proprietary platforms for editing hematopoietic stem cells and T cells, as well as an RNA base editing approach for in vivo applications. EdiGene's innovative methods enable targeted modifications of genetic information in human cells and facilitate high-throughput drug discovery through advanced screening techniques. By translating these technologies into novel therapeutics, EdiGene aims to improve the safety and efficacy of gene therapy, ultimately benefiting patients, the pharmaceutical industry, and the scientific research community.

Xiaoxian Dun is a healthy food products company that develops products from bird's nests. The company focuses on researching and developing a way to make a bowl of bird's nests that are just as good as a stew pot's slow-cooked bird's nest so that more people can enjoy it. The company seeks to revive and expand the conventional bird's nest market.

Arctic Vision is a clinical-stage specialty ophthalmology company based in China, focused on developing innovative therapies to meet the unmet clinical needs in ophthalmic diseases. The company boasts a leading portfolio of breakthrough technologies aimed at addressing various eye care challenges in China, Asia, and globally. Established by prominent life sciences investors, Arctic Vision is guided by a team of experienced professionals from the ophthalmic industry, who possess extensive knowledge in research and development as well as commercialization of eye care products. The company's efforts include the development of new ophthalmic medicines, particularly gene therapies, that hold significant commercial potential and aim to improve the recovery outcomes for patients with rare ophthalmic conditions.

MediLink Therapeutics is a China-based developer of antibody-drug conjugates (ADC) focused on cancer therapy. The company advances next-generation ADCs and aims to address unmet medical needs in China, while pursuing global value through multicenter clinical trials and cross-border collaborations. Its R&D center is in Suzhou.

Regor Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for oncology, metabolic diseases, and autoimmune diseases. The company utilizes its proprietary CARD (Computer Accelerated Rational Discovery) platform, which integrates structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development to create clinically differentiated therapeutics. With a world-class scientific team, Regor Therapeutics is committed to efficiently producing both best-in-class and first-in-class molecules, advancing its mission to improve patient outcomes through novel therapeutic solutions.

Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the research and development and subversive production of rAAV gene drugs. Zhishan Weixin's therapeutic areas cover blood diseases, rare diseases, and other disease areas.

CARsgen Therapeutics, Ltd. is a clinical-stage biopharmaceutical company specializing in the development of chimeric antigen receptor T-cell (CAR-T) therapeutics for cancer treatment. Based in Shanghai, China, the company focuses on innovative immunotherapy solutions that harness the body's immune system to target and eliminate cancer cells. CARsgen's CAR-T technology is designed to direct T cells to recognize and attack tumors based on specific cell surface proteins, targeting conditions such as hepatocellular carcinoma (HCC) and lung squamous cell carcinoma, among others. The company has made significant advancements in CAR-T development, including the completion of the world's first dose-ascending injection tests for HCC and exclusive trials for glioblastoma multiforme in China. Through partnerships with notable institutions like the Shanghai Cancer Institute and Shanghai Renji Hospital, CARsgen Therapeutics aims to position itself at the forefront of cancer therapeutics both in China and internationally.

Zhaoke Ophthalmology Pharmaceutical is a Pharmaceutical platform.

Chinese sorghum spirit producer from Chongqing. Specializing in innovated light-aroma baijius with creative presentation.

Sinovent, established in 2016, is a global biopharmaceutical company with headquarters in Suzhou, China, and offices in Beijing, China, and Boston, U.S.A. It specializes in developing advanced treatments for global healthcare challenges, with a focus on oncology, autoimmune diseases, and infectious diseases. Sinovent's portfolio comprises 12 products in various stages of development, leveraging its expertise in science, management, and finance to deliver innovative solutions to patients worldwide.

OBiO Technology is a biotechnology company based in Shanghai that specializes in viral-based gene therapy. It offers comprehensive Contract Research Organization (CRO) services, focusing on the development of gene therapy vectors, gene function research, and drug efficacy studies. The company also provides Contract Development and Manufacturing Organization (CDMO) services, which include process development, testing, and clinical sample GMP production. OBiO Technology supports the research and development of genetic drugs, facilitating advancements in gene therapy through its expertise in both foundational research and practical applications within the biopharmaceutical industry.

JW Therapeutics (Shanghai) Co., Ltd. is a biotechnology company based in Shanghai, China, specializing in the development, transformation, and promotion of cell-based immunotherapies. The company focuses on innovative therapies that utilize chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to enhance the body's immune response against cancer. JW Therapeutics is dedicated to creating transformative treatments for both hematological cancers and solid tumors, with its lead product candidate being relmacabtagene autoleucel, a CAR-T therapy targeting anti-CD19. By advancing these groundbreaking therapies, JW Therapeutics aims to improve survival rates and quality of life for cancer patients.

Heyuan Biotechnology is a biotechnology company focusing on the field of gene therapy services. They offer gene therapy vectors, gene function research, drug targets, and efficacy for the basic research of gene therapy research, among other services.

Hygeia Healthcare Group is a leading oncology-focused healthcare group in China. The company operates its own hospitals, provides third-party radiotherapy service, and manages partner hospitals. Its core business consists of 7 oncology hospitals and 3 managed hospitals in in 6 provinces in China. In addition, the company provides services to 15 hospital partners (including managed hospitals) in 9 provinces of China on its radiotherapy centers.

Beaver Education is an online education company focused on delivering high-quality teaching services for elementary and middle school students, as well as educational institutions. The company offers a range of products, including online subject training courses and personalized tutoring tools. Its platform features two key modules: a process evaluation module and a personalized learning module. Additionally, it includes a teaching management and quality monitoring module, which provides educators with essential management information and data analysis tools. This comprehensive approach aims to enhance the learning outcomes of students and support teachers in their daily management tasks.

Mabwell Biotech is a Chinese innovative biopharmaceutical company based in Shanghai Zhangjiang Hi-Tech Park. Since its establishment in 2017, it has absorbed and newly established nine biopharmaceutical R&D and production enterprises. At present, the company focuses on the development and manufacturing of macromolecular drugs such as therapeutic monoclonal antibodies and long-acting recombinant proteins. There are more than thirty varieties of drugs at different stages of development covering tumor, autoimmunity, anti-infection and ophthalmic diseases. Among them, six of them have entered the clinical stage, and three of them are in Phase III clinical trials.

Pop Mart designs, produces, and sells pop-culture figure toys based on intellectual properties. It operates an integrated platform covering the designer toy value chain, including acquiring and incubating IPs, creating original concepts, and licensing rights from IP owners. The company collaborates with IP holders to develop and release collectible figures and related products. Originating in China, Pop Mart has expanded to Southeast Asia and North America, and it also diversifies into accessories, building blocks, and theme park operations to broaden revenue. The business focuses on IP-driven toy lines and scalable partnerships to sustain growth.

Perfect Diary is an e-commerce-based cosmetic brand. The company is committed to exploring the trends in international cosmetics and the frontiers of fashion to provide easy-to-use cosmetics products for young Asian women.Perfect Diary is professional in branding and online traffic management. By launching co-branded cosmetic products with KOLs, idols and even some famous organizations like the British Museum

Abbisko Therapeutics is a clinical-stage biopharmaceutical company focused on discovery and development of differentiated small-molecule oncology therapies. Based in Shanghai, China, and founded in 2016, the company emphasizes immuno-oncology and aims to advance cancer treatments through in-house research and development, with a focus on therapies for hepatocellular carcinoma and solid tumors.

RemeGen, Ltd. is a biopharmaceutical company based in Yantai, Shandong Province, China, focused on addressing unmet medical needs for patients with life-threatening conditions. The company specializes in the research, development, manufacturing, and commercialization of innovative biologics, particularly monoclonal antibodies and antibody-drug conjugates. RemeGen's leading products include Telitacicept, aimed at treating systemic lupus erythematosus, and Disitamab Vedotin, designed for various cancers. The company’s therapeutic offerings target significant health issues, including autoimmune diseases, oncology, and ophthalmology. With operations in both China and the United States, RemeGen primarily generates its revenue from the Chinese market.

Kaishuo Jianggushi is a children's content provider. Also known as Kaishu Story, the brand is focusing on children’s stories with additional products such as audio series and online parenting courses.

Juvenile is a learning and counseling application for primary and secondary schools, mainly for 7-15 year olds. The application covers the knowledge points and exam focus of each subject in primary and secondary schools, and answers the test proposition in detail. The knowledge coverage can meet the needs of further studies, and can also help students to self-study after class. The app also provides students with effective learning method guidance, audio books and learning materials.

Akeso Biopharma, Inc. is a contract research organization based in Zhongshan, China, specializing in the discovery and development of antibody and protein drugs. Established in 2012, the company offers a range of integrated services to both domestic and international pharmaceutical firms, including protein expression and purification, antibody generation, assay development, humanization, and affinity maturation. Akeso has developed a comprehensive biopharmaceutical research and development platform, focusing on therapeutic areas such as cancer, autoimmune diseases, inflammation, and cardiovascular diseases. With a robust pipeline of over 30 drug candidates, 17 of which are in clinical stages, Akeso is recognized for its innovative approaches, including the development of first-in-class bi-specific antibody drugs. The company collaborates with various pharmaceutical enterprises to advance the joint development of new drugs, positioning itself as a leader in the biopharmaceutical industry.

Mahua Fun Age, the largest drama agency in China, was founded in 2003 and has produced popular dramas and movies such as "Clown Loves Beauty", "Count of Mountain Wulong", "Dream of those Years", "Xialuo’s trouble", and "Donkey water". With a strong portfolio of over 20 high-quality original shows and intellectual properties, Mahua Fun Age has established a significant presence in the entertainment industry. In 2016 alone, the company organized more than 1,600 tour shows across China, showcasing its creativity and appeal to a wide audience.

Allist Pharmaceuticals is a pharmaceutical company based in Shanghai that focuses on discovering, developing, and commercializing innovative medicines, particularly in the field of cancer treatment. The company is driven by the unmet clinical needs within the global pharmaceutical market and is committed to advancing long life through scientific and technological innovation. Allist Pharmaceuticals aims to create safe, effective, and inclusive drugs, holding independent intellectual property rights for its products.

NetEase Cloud Music, established in 2013 and based in Hangzhou, China, specializes in online music streaming services through its mobile application. The platform enables users to access a wide variety of music and offers additional features, such as music discovery and social networking capabilities. As a subsidiary of NetEase, Inc., NetEase Cloud Music has grown to become a significant player in the Chinese music streaming market, catering to the evolving preferences of its audience while developing applications for smartphones to enhance user experience.

Juvenile is a learning and counseling application for primary and secondary schools, mainly for 7-15 year olds. The application covers the knowledge points and exam focus of each subject in primary and secondary schools, and answers the test proposition in detail. The knowledge coverage can meet the needs of further studies, and can also help students to self-study after class. The app also provides students with effective learning method guidance, audio books and learning materials.

Infinovo, established in 2016, specializes in the development of advanced biosensors and application products for the healthcare sector, particularly focusing on chronic disease detection and management. The company is dedicated to creating accurate and affordable Continuous Glucose Monitoring (CGM) systems for patients with Type 1 and Type 2 diabetes. Infinovo's CGM technology is designed to compete globally in terms of accuracy, durability, and design, aiming to enhance diagnostic precision and improve treatment outcomes for users. By providing innovative sensor tools, Infinovo seeks to facilitate better healthcare solutions for individuals managing chronic conditions.

EVE Energy is a China-based battery company focused on research, manufacturing, and sale of consumer, power, and energy storage batteries. Its product portfolio includes lithium primary cells such as lithium thionyl chloride, lithium manganese dioxide, and lithium iron disulfide; lithium ion cells in cylindrical, pouch, and prismatic formats with aluminum shells and polymer variants. The company also develops energy storage systems for home use, telecom backup, micro grids, and industrial needs, and power systems for electric vehicles, buses, and light vehicles. Applications span smart metering, intelligent transportation, security, smart home, oil drilling, GPS, medical devices, and defense, with lithium ion cells used in energy storage and automotive electronics. EVE positions itself as a national high tech enterprise and a leading lithium primary battery producer, especially in lithium thionyl chloride cells. Founded in 2001 and based in Huizhou, it has invested heavily in power storage and embraces automated, information driven manufacturing to serve global customers.

Abbisko Therapeutics is a clinical-stage biopharmaceutical company focused on discovery and development of differentiated small-molecule oncology therapies. Based in Shanghai, China, and founded in 2016, the company emphasizes immuno-oncology and aims to advance cancer treatments through in-house research and development, with a focus on therapies for hepatocellular carcinoma and solid tumors.

Jinfuzi is an online investment platform that provides users with access to a diverse range of financial products, including private equity, venture capital, trusts, and foreign funds. The platform is designed to assist investors in selecting investment portfolios that align with their individual return-risk preferences. Jinfuzi offers two main mobile applications: Finance Port and Snowball, which facilitate the investment process and enhance user engagement. By focusing on wealth management services, Jinfuzi aims to simplify the investment experience for its users and enable them to make informed financial decisions.

Wajijia Entertainment provides network and entertainment production services. Their businesses include producing television content and music videos that enable consumers to enjoy a variety of entertainment content and music.

InnoCare is a biopharmaceutical company based in China, focused on the discovery and development of innovative treatments for cancer and autoimmune diseases. The company boasts a highly skilled scientific team with extensive drug innovation experience in both the United States and China, supported by a distinguished Scientific Advisory Board composed of experts from top universities, hospitals, and the pharmaceutical industry. InnoCare's product pipeline includes a range of therapies, such as orelabrutinib, zanubrutinib, and tafasitamab, targeting hematological tumors, solid tumors, and autoimmune diseases. The company aims to make significant advancements in the treatment of conditions related to abnormal B-cell and T-cell functions, thereby contributing to the global fight against these diseases.

Dedao manufactures auto parts. Their products include inspection tools, towing hooks, waveform crash barriers, threshold stiffeners, and roller beams. They provide sales, research, and development services.

Immupeutics Medical Technology Co., Ltd. is a biomedical research company specializing in tumor immunotherapy. The firm is dedicated to the research and development of immune cell therapy drugs targeting various types of tumors. In addition to its primary focus on therapeutic agents, Immupeutics also invests in companion diagnostic technology and immunological multi-omics technology. By integrating these innovative approaches, the company aims to enhance patient outcomes through the provision of advanced immune cell therapies and comprehensive treatment methodologies.

ByteDance is a technology company that develops and operates a range of content platforms, most notably TikTok and Douyin. It aims to enhance user experiences through innovative technology, allowing individuals to connect, create, and consume content seamlessly. The company specializes in mobile applications that cater to online media, entertainment, and social networking, leveraging artificial intelligence to deliver personalized content that aligns with users' preferences. In addition to its flagship platforms, ByteDance provides tools that facilitate content creation and collaboration, reflecting its commitment to enriching lives through technology.

Linklogis is a technology-driven provider of supply chain finance in China. The company uses data, artificial intelligence, and blockchain to build a financial services platform that directly connects the asset side with the fund side, enabling small enterprises to obtain funding more conveniently. It operates in two segments: supply chain finance technology solutions and emerging solutions. Its technology solutions include Anchor Cloud and FI Cloud, while its emerging solutions encompass Crossborder Cloud and SME credit tech solutions. By focusing on practical use cases and scalable digital infrastructure, Linklogis supports supplier and buyer financing within supply chains and expands access to capital for small businesses.

WeShare is a Chinese financial services provider that specializes in enhancing the capabilities of consumer financial institutions. The company focuses on enabling both onshore and offshore institutional investors to efficiently and securely invest in China's consumer finance sector. By leveraging advanced technology and data analysis, WeShare aims to improve customer access, risk management, and funding solutions. Committed to developing top-tier fintech capabilities, WeShare collaborates with industry partners to foster shared growth and mutual benefits in the financial services landscape.

Teligene Ltd., established in 2011 and headquartered in Jiangsu, China, is a pharmaceutical research and development company specializing in the creation of small-molecule drugs for oncology. The company's senior management team, experienced in advanced drug development technologies, focuses on researching and developing innovative, targeted anti-tumor drugs with independent intellectual property rights.

Chaodian Culture operates as a provider of content creation services, specializing in the development of cultural products and animation derivatives. The company is also involved in planning and organizing events, including flagship concerts and various exhibitions, which allow companies to showcase a range of cultural products and other content. By facilitating these platforms, Chaodian Culture enables content creators to effectively present their work to a broader audience.

Shanghai Henlius Biotech, Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the research, development, production, and commercialization of biologics, particularly monoclonal antibody (mAb) biosimilars and novel therapies. Founded in 2010, the company focuses on oncology and autoimmune diseases, offering products such as HLX01, a biosimilar for treating non-Hodgkin lymphoma. Henlius is actively advancing its pipeline, with multiple products under review for regulatory approval, alongside conducting numerous clinical studies for various therapies. The company collaborates with partners, including agreements to develop treatments for COVID-19 and eye diseases. Shanghai Henlius Biotech is a joint venture between Shanghai Fosun Pharmaceutical and Henlius Biopharmaceuticals, established in 2009, and operates out of the Shanghai Caohejing High-Technology Park.

Sinovent, established in 2016, is a global biopharmaceutical company with headquarters in Suzhou, China, and offices in Beijing, China, and Boston, U.S.A. It specializes in developing advanced treatments for global healthcare challenges, with a focus on oncology, autoimmune diseases, and infectious diseases. Sinovent's portfolio comprises 12 products in various stages of development, leveraging its expertise in science, management, and finance to deliver innovative solutions to patients worldwide.

Immune-Onc Therapeutics, Inc. is a biopharmaceutical company based in Palo Alto, California, founded in 2016. The company specializes in the discovery and development of innovative biologic treatments, particularly aiming to create therapeutic antibodies for cancer. Immune-Onc Therapeutics leverages scientific insights related to the tumor microenvironment and immune suppressive pathways to develop first-in-class biotherapeutics. By targeting myeloid cells, it aims to disarm immune suppression within tumors, facilitating new immunomodulatory approaches for cancer treatment. The company's focus on advancing novel immuno-oncology products positions it to provide effective new treatment options for cancer patients.

Innomed medical niche markets' products and services. They continue to provide consumers with helpful advice and assistance in their department so that they can carry out their care as as possible. For global medical startup firms, they complete late-stage commercialization partners.

Kaishuo Jianggushi is a children's content provider. Also known as Kaishu Story, the brand is focusing on children’s stories with additional products such as audio series and online parenting courses.

The #1 international kindergarten in Beijing

Didi Chuxing, founded in 2012 in Beijing, is a leading mobile transportation platform providing app-based services such as taxi hailing, private car-hailing, social ride-sharing, car rental, and enterprise solutions. With over 450 million users and daily orders reaching 25 million, Didi offers a variety of mobility options to optimize resource allocation through big data-driven algorithms. The company aims to address transportation, environmental, and employment challenges by collaborating with communities and partners. Acquiring Uber China in 2016, Didi has over 21 million drivers and car owners on its platform, generating income while offering convenient transportation solutions to users worldwide.

GeneCast Biotechnology Co., Ltd. is a Beijing-based company founded in 2014, specializing in gene research and cancer diagnostics. The company offers a technology platform for cell-free DNA next-generation sequencing (NGS) tests, which include companion diagnostics, genetic profiling, prognosis, and monitoring for various solid tumors. GeneCast provides solutions for cancer treatment and genetic testing, focusing on tumors such as lung, colorectal, liver, and breast cancers. Its non-invasive diagnostic methods leverage high-throughput sequencing and bioinformatics to enable personalized medicine, aiming to improve patient outcomes and quality of life. The company collaborates with hospitals and research institutions to advance its capabilities in detecting tumors and cancer-related genes in blood.

JW Therapeutics (Shanghai) Co., Ltd. is a biotechnology company based in Shanghai, China, specializing in the development, transformation, and promotion of cell-based immunotherapies. The company focuses on innovative therapies that utilize chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to enhance the body's immune response against cancer. JW Therapeutics is dedicated to creating transformative treatments for both hematological cancers and solid tumors, with its lead product candidate being relmacabtagene autoleucel, a CAR-T therapy targeting anti-CD19. By advancing these groundbreaking therapies, JW Therapeutics aims to improve survival rates and quality of life for cancer patients.

Established in October 2013, Sugarman Media is a comprehensive film and television organization integrating film and television planning, production and distribution, post-production, entertainment marketing, and performing arts brokerage. The company's main business is the production of online dramas, and has produced two explosive works "The Hurry" and "The Best of Us". The company has the ability to continue to produce high-quality content, and will be committed to creating high-quality film and television IP through a series of plays in the future.

The Child Academy provides a developmentally appropriate learning environment where all children's emotional, social, physical, and intellectual needs are satisfied in a supportive, artistic environment. They employ a combination of play-based and literacy activities to build self-esteem, critical thinking, problem solving, and management skills in an atmosphere that incorporates scheduled, routine, and open discovery activities.

Leading financial and insurance technology company in China

Phyplus Inc., established in 2015 and headquartered in Shanghai, China, specializes in the design and development of high-performance, low-power communication chips and programs. The company focuses on creating mixed-signal integrated circuits and system-on-chips tailored for Internet of Things (IoT) smart terminals. Phyplus is dedicated to delivering innovative low-power Bluetooth solutions that prioritize minimal energy consumption while achieving high integration and an optimal price-to-performance ratio. Through its advanced technology, the company aims to enhance the functionality and efficiency of connected devices in the growing IoT market.

Gaosi Education Group is a Chinese educational institution specializing in extracurricular tutoring for middle and primary school students. Founded in December 2009, it is headquartered in Beijing's Haidian District. The group focuses on gifted education, offering tailored courses for students from primary through junior high school. It features personalized one-on-one teaching centers and emphasizes mathematics competitions as a key component of its curriculum. With nearly 10,000 students enrolled, Gaosi Education Group employs around 100 full-time teachers and staff dedicated to teaching and research.

Linklogis is a technology-driven provider of supply chain finance in China. The company uses data, artificial intelligence, and blockchain to build a financial services platform that directly connects the asset side with the fund side, enabling small enterprises to obtain funding more conveniently. It operates in two segments: supply chain finance technology solutions and emerging solutions. Its technology solutions include Anchor Cloud and FI Cloud, while its emerging solutions encompass Crossborder Cloud and SME credit tech solutions. By focusing on practical use cases and scalable digital infrastructure, Linklogis supports supplier and buyer financing within supply chains and expands access to capital for small businesses.

Pipilu is a company dedicated to providing entertainment content and products specifically designed for children in China. It focuses on producing original publishing materials, movies, animations, and various consumer products. By prioritizing quality in its offerings, Pipilu aims to deliver engaging and entertaining experiences that cater to the interests and needs of young audiences.

Established in 2013, Studio 9 is a leading original animation IP creation company. It has the highest-yield production line of comics and 2D & 3D animation in China. The company has built its IP production committee to further expand the value of its IP in animation, movies and games. It has also successfully created China's first action animation IP " The Outcast ", and hot IPs such as “No”, “Heaven to Earth”, etc.

Avary Holding is a joint-stock firm that is involved in printed circuit board design, research, development, manufacturing, and sales. The primary products of the company are communication boards, boards for computers and consumer electronics, and other boards. Additionally, these goods are primarily used in downstream goods including mobile phones, network equipment, tablets, wearable tech, notebook computers, servers, storage, automotive electronics, and others. Both domestically and internationally, the company distributes its goods.

Beijing Haixue Education Technology Co., Ltd. is a private company based in China that operates the Haixue platform, which focuses on providing employment and career development solutions for students and professionals. The platform leverages a combination of live lectures and high-definition broadcasting to enhance its training offerings. Utilizing artificial intelligence and big data analysis, Haixue creates personalized learning experiences, recommending challenging knowledge points to users. The company specializes in skill training across various fields, including construction, accounting, law, and health, allowing learners to acquire knowledge and experience efficiently. Through its innovative approach, Haixue aims to systematically enhance the workplace value of individuals and groups.

ECNUAS is a global private boarding institution that caters to students from kindergarten through high school. The primary objective of the school is to establish a Chinese educational model that has a significant impact on the world. It combines the finest elements of both Eastern and Western educational philosophies and methodologies, while also identifying and leveraging high-quality educational resources at local, national, and international levels.

iDreamSky Technology, established in 2009 and headquartered in Shenzhen, China, is a leading digital entertainment platform in the Chinese game publishing market. It specializes in publishing third-party licensed and self-developed games, spanning genres like role-playing, puzzle, and casual competition, to players through various mobile channels and other publishers. As of 2019, its portfolio comprised 60 games. Additionally, iDreamSky offers digital content services, advertising, and other information services. It has collaborated with major clients such as Lenovo, China Telecom, and HTC. In 2011, it launched Skynet, a one-stop solution for game developers to expand and establish their businesses in China, following a seed investment of $2 million from Hwa Xiu Investment Group.

Xinshixiang is a well-known brand in the content field which has extended from textual content manufacturing to famous events. The company's platform provides contents including personalized recommendation, emotional companionship, value puzzlement solutions, enabling the young generation to achieve self-worth through reading.

Luogic Thinking is China’s #1 online producer of educational podcasts.

Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in Shanghai, China, focusing on the discovery, development, and commercialization of innovative drugs. The company operates in various therapeutic areas, including oncology, metabolic disorders, autoimmune diseases, and neurologic conditions. Junshi's notable products include JS001, a recombinant humanized anti-PD-1 monoclonal antibody marketed as TUOYIR for several cancers, and UBP1211, a biosimilar of Humira currently in Phase I clinical trials for rheumatoid arthritis and related conditions. Additionally, the company is advancing other drug candidates, such as JS002, a monoclonal antibody for hyperlipidemia, and several others in early-phase trials targeting various diseases. Junshi has established collaborations with leading pharmaceutical companies, including Eli Lilly and Merck, to develop therapeutic antibodies and explore new treatment combinations. Founded in 2012, Shanghai Junshi Biosciences is committed to addressing unmet medical needs through its extensive research and development initiatives.

China Mercy Health Group is a healthcare organization founded by Liu Xiaocheng, who has significant experience in medical administration, including roles at the Chinese Academy of Medical Sciences and China Union Medical University. The group is primarily focused on enhancing the efficiency of medical institutions in China through a comprehensive hospital management service platform. Its offerings encompass various aspects of hospital operations, including architectural design, management consultancy, training for healthcare professionals, and logistics for medical supplies. By providing these services, China Mercy Health Group aims to create an optimal healthcare environment that improves patient outcomes and supports the healthcare infrastructure in the region.

Sound Solutions, a subsidiary of [Dover Corporation](/organization/dover)'s Knowles Electronics and formerly owned by [NXP](/organization/nxp), manufactures speakers and receivers for cell phones and other electronic devices.

Wenzhou Kangning Hospital operates and manages a network of healthcare facilities in China with a focus on psychiatric specialty care and related mental health services. The group runs owned hospitals and offers elderly rehabilitation services and other healthcare-related activities across multiple regions, generating revenue mainly from operating its hospitals and related healthcare businesses. Its services encompass a range of psychiatric care offerings, including gender-specific psychiatry, addiction treatment, geriatric psychiatry, depression and sleep clinics, child and adolescent psychology, as well as teleconsultation. Founded in 1996 and based in Wenzhou, the company aims to expand access to psychiatric care through its network.

Linklogis is a technology-driven provider of supply chain finance in China. The company uses data, artificial intelligence, and blockchain to build a financial services platform that directly connects the asset side with the fund side, enabling small enterprises to obtain funding more conveniently. It operates in two segments: supply chain finance technology solutions and emerging solutions. Its technology solutions include Anchor Cloud and FI Cloud, while its emerging solutions encompass Crossborder Cloud and SME credit tech solutions. By focusing on practical use cases and scalable digital infrastructure, Linklogis supports supplier and buyer financing within supply chains and expands access to capital for small businesses.

Bilibili Inc. is an online entertainment platform based in Shanghai, China, that caters primarily to the younger generations. Founded in 2009, it began as a community focused on anime, comics, and gaming (ACG), but has since broadened its offerings to include a wide variety of content such as videos, live broadcasting, and mobile games. The platform emphasizes high-quality content and fosters strong emotional connections among its users, creating a vibrant community. Bilibili generates revenue through multiple channels, including advertising, gaming, live streaming, value-added services, and e-commerce. The company has also formed a strategic collaboration with Tencent for sharing and operating anime and games, enhancing its content library and user experience.